 Neurological Disorder Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033
The global Neurological Disorder Drugs Market is gaining strong attention as neurological diseases become a major healthcare priority across developed and emerging economies. The market is valued a... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global Neurological Disorder Drugs Market is gaining strong attention as neurological diseases become a major healthcare priority across developed and emerging economies. The market is valued at US$ 105.8 Bn in 2026 and is projected to reach US$ 159.1 Bn by 2033, growing at a CAGR of 6.00% during the forecast period. The rising prevalence of epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, migraine, neuropathic pain, amyotrophic lateral sclerosis, Huntington’s disease, and other neurological disorders is increasing the need for effective drug therapies.Neurological disorder drugs play an essential role in managing symptoms, improving patient stability, reducing disease-related complications, and supporting long-term care. As neurological conditions often require continuous treatment, the market is supported by recurring prescriptions, specialist consultations, hospital-based treatment, and expanding access through retail and online pharmacy channels. Market Insights The Neurological Disorder Drugs Market covers a wide range of therapeutic categories, including antiepileptic drugs, antipsychotic drugs, antidepressants, anticholinergic drugs, cholinesterase inhibitors, NMDA receptor antagonists, analgesics, hypnotics and sedatives, anticoagulants, antihypertensive drugs, and other treatment options. These medicines are used across both chronic and acute neurological conditions, making the market broad, diversified, and clinically important. Oral drugs continue to account for significant demand due to ease of administration, patient convenience, and suitability for long-term disease management. Parenteral drugs are also gaining importance in hospital settings, specialty clinics, and advanced neurological care, especially where rapid action, biologic therapy, or supervised administration is required. The market is being shaped by growing awareness of neurological symptoms, better diagnostic capabilities, and improved treatment access. Patients are increasingly seeking medical attention for memory loss, seizures, tremors, chronic headaches, nerve pain, mood-related neurological symptoms, and movement disorders. This is encouraging earlier diagnosis and stronger demand for both established and newer drug classes. Drivers A key driver of the Neurological Disorder Drugs Market is the increasing burden of neurological diseases among aging populations. Alzheimer’s disease, Parkinson’s disease, cerebrovascular disease, and neuropathic pain are becoming more common as life expectancy rises. At the same time, conditions such as epilepsy, migraine, multiple sclerosis, and psychiatric-neurological disorders are being diagnosed more frequently due to improved awareness and medical screening. Another major growth factor is pharmaceutical innovation. Companies are investing in new drug candidates, improved formulations, targeted therapies, and advanced delivery systems to address unmet medical needs. In areas such as multiple sclerosis, migraine, epilepsy, and neurodegenerative disorders, newer therapies are helping physicians personalize treatment based on disease severity, patient response, safety, and tolerability. The growth of specialty clinics and neurology departments is also supporting market expansion. These care settings improve diagnosis, treatment selection, therapy monitoring, and patient follow-up. In addition, hospital pharmacies, retail pharmacies, and online pharmacies are improving medicine availability, making it easier for patients to maintain regular treatment schedules. Business Opportunity The Neurological Disorder Drugs Market offers strong opportunities for pharmaceutical companies that can develop therapies with better efficacy, fewer side effects, improved adherence, and convenient dosing. Neurodegenerative diseases remain a high-potential area because many patients still have limited treatment options. Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple sclerosis are expected to remain key focus areas for research-driven companies. There is also significant opportunity in generic and branded generic drugs. Many neurological conditions require lifelong or long-term treatment, making affordability an important factor for patients and healthcare systems. Companies with strong manufacturing capabilities, regulatory expertise, and distribution networks can expand access to antiepileptic drugs, antidepressants, antipsychotic drugs, analgesics, antihypertensive drugs, and other commonly prescribed neurological therapies. Digital healthcare and pharmacy-based services are creating additional business potential. Online pharmacies, refill reminders, patient education programs, and adherence support tools can help improve therapy continuation. Companies that combine drug supply with patient support and disease management services may strengthen their competitive position in the coming years. Region Analysis North America is expected to remain a leading market for neurological disorder drugs due to advanced healthcare infrastructure, high diagnosis rates, strong reimbursement support, and significant research activity. The region benefits from the presence of major pharmaceutical companies, specialized neurology centers, and active clinical development programs. Early adoption of innovative therapies further strengthens market growth. Europe also holds a strong position in the market, supported by aging populations, structured healthcare systems, and rising focus on neurological disease management. Demand is driven by treatment needs across Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, migraine, and other chronic neurological conditions. Public healthcare coverage and clinical guidelines support wider access to approved therapies. Asia Pacific is expected to present substantial growth opportunities during the forecast period. Large patient populations, rising healthcare spending, improving medical infrastructure, and growing awareness of neurological diseases are supporting market development. Expanding hospital networks, specialty clinics, and pharmacy channels are also improving treatment access across the region. Latin America and the Middle East & Africa are gradually expanding as healthcare systems improve and neurological disease awareness increases. Better availability of medicines, rising hospital investments, and broader pharmacy networks are expected to support steady demand in these regions. Key Players The Neurological Disorder Drugs Market is highly competitive, with major pharmaceutical companies focusing on product development, clinical research, strategic collaborations, and geographic expansion. Key players include: • Pfizer Inc. • Novartis AG • Johnson & Johnson • Eli Lilly and Company • AbbVie Inc. • Merck & Co., Inc. • Teva Pharmaceutical Industries Ltd. • UCB S.A. • Biogen Inc. • Sanofi S.A. • F. Hoffmann-La Roche Ltd. • Takeda Pharmaceutical Company Limited • Otsuka Pharmaceutical Co., Ltd. • Lundbeck A/S • Neurocrine Biosciences, Inc. These companies are strengthening their neurology portfolios through innovation, lifecycle management, and expansion into high-demand therapeutic areas. Their focus on unmet needs and advanced treatment options is expected to influence future market competition. Segmentation By Drug Class • Antiepileptic Drugs • Antipsychotic Drugs • Antidepressants • Anticholinergic Drugs • Cholinesterase Inhibitors • NMDA Receptor Antagonists • Analgesics • Hypnotics & Sedatives • Anticoagulants • Antihypertensive Drugs • Others By Disease Type • Epilepsy • Alzheimer’s Disease • Parkinson’s Disease • Multiple Sclerosis • Cerebrovascular Disease • Migraine • Neuropathic Pain • Amyotrophic Lateral Sclerosis • Huntington’s Disease • Others By Route of Administration • Oral • Parenteral • Others By End User • Hospitals • Specialty Clinics • Homecare Settings • Others By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Neurological Disorder Drugs Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Neurological Disorder Drugs Market Outlook, 2020 - 2033 3.1. Global Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 3.1.1. Oral 3.1.2. Parenteral 3.1.3. Others 3.2. Global Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.2.1. Hospitals 3.2.2. Specialty Clinics 3.2.3. Homecare Settings 3.2.4. Others 3.3. Global Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 3.3.1. Antiepileptic Drugs 3.3.2. Antipsychotic Drugs 3.3.3. Antidepressants 3.3.4. Anticholinergic Drugs 3.3.5. Cholinesterase Inhibitors 3.3.6. NMDA Receptor Antagonists 3.3.7. Analgesics 3.3.8. Hypnotics & Sedatives 3.3.9. Anticoagulants 3.3.10. Others 3.4. Global Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 3.4.1. Epilepsy 3.4.2. Alzheimer’s Disease 3.4.3. Parkinson’s Disease 3.4.4. Multiple Sclerosis 3.4.5. Cerebrovascular Disease 3.4.6. Migraine 3.4.7. Neuropathic Pain 3.4.8. Amyotrophic Lateral Sclerosis 3.4.9. Huntington’s Disease 3.4.10. Others 3.5. Global Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 3.5.1. Hospital Pharmacies 3.5.2. Retail Pharmacies 3.5.3. Online Pharmacies 3.5.4. Others 3.6. Global Neurological Disorder Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Latin America 3.6.5. Middle East & Africa 4. North America Neurological Disorder Drugs Market Outlook, 2020 - 2033 4.1. North America Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 4.1.1. Oral 4.1.2. Parenteral 4.1.3. Others 4.2. North America Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.2.1. Hospitals 4.2.2. Specialty Clinics 4.2.3. Homecare Settings 4.2.4. Others 4.3. North America Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 4.3.1. Antiepileptic Drugs 4.3.2. Antipsychotic Drugs 4.3.3. Antidepressants 4.3.4. Anticholinergic Drugs 4.3.5. Cholinesterase Inhibitors 4.3.6. NMDA Receptor Antagonists 4.3.7. Analgesics 4.3.8. Hypnotics & Sedatives 4.3.9. Anticoagulants 4.3.10. Others 4.4. North America Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 4.4.1. Epilepsy 4.4.2. Alzheimer’s Disease 4.4.3. Parkinson’s Disease 4.4.4. Multiple Sclerosis 4.4.5. Cerebrovascular Disease 4.4.6. Migraine 4.4.7. Neuropathic Pain 4.4.8. Amyotrophic Lateral Sclerosis 4.4.9. Huntington’s Disease 4.4.10. Others 4.5. North America Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 4.5.1. Hospital Pharmacies 4.5.2. Retail Pharmacies 4.5.3. Online Pharmacies 4.5.4. Others 4.6. North America Neurological Disorder Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.6.1. U.S. Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 4.6.2. U.S. Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 4.6.3. U.S. Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 4.6.4. U.S. Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 4.6.5. U.S. Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 4.6.6. Canada Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 4.6.7. Canada Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 4.6.8. Canada Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 4.6.9. Canada Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 4.6.10. Canada Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 4.7. BPS Analysis/Market Attractiveness Analysis 5. Europe Neurological Disorder Drugs Market Outlook, 2020 - 2033 5.1. Europe Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 5.1.1. Oral 5.1.2. Parenteral 5.1.3. Others 5.2. Europe Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.2.1. Hospitals 5.2.2. Specialty Clinics 5.2.3. Homecare Settings 5.2.4. Others 5.3. Europe Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 5.3.1. Antiepileptic Drugs 5.3.2. Antipsychotic Drugs 5.3.3. Antidepressants 5.3.4. Anticholinergic Drugs 5.3.5. Cholinesterase Inhibitors 5.3.6. NMDA Receptor Antagonists 5.3.7. Analgesics 5.3.8. Hypnotics & Sedatives 5.3.9. Anticoagulants 5.3.10. Others 5.4. Europe Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 5.4.1. Epilepsy 5.4.2. Alzheimer’s Disease 5.4.3. Parkinson’s Disease 5.4.4. Multiple Sclerosis 5.4.5. Cerebrovascular Disease 5.4.6. Migraine 5.4.7. Neuropathic Pain 5.4.8. Amyotrophic Lateral Sclerosis 5.4.9. Huntington’s Disease 5.4.10. Others 5.5. Europe Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 5.5.1. Hospital Pharmacies 5.5.2. Retail Pharmacies 5.5.3. Online Pharmacies 5.5.4. Others 5.6. Europe Neurological Disorder Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.6.1. Germany Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.2. Germany Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.3. Germany Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.4. Germany Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.5. Germany Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.6. Italy Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.7. Italy Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.8. Italy Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.9. Italy Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.10. Italy Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.11. France Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.12. France Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.13. France Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.14. France Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.15. France Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.16. U.K. Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.17. U.K. Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.18. U.K. Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.19. U.K. Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.20. U.K. Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.21. Spain Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.22. Spain Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.23. Spain Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.24. Spain Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.25. Spain Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.26. Russia Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.27. Russia Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.28. Russia Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.29. Russia Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.30. Russia Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.6.31. Rest of Europe Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 5.6.32. Rest of Europe Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 5.6.33. Rest of Europe Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 5.6.34. Rest of Europe Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 5.6.35. Rest of Europe Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 5.7. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Neurological Disorder Drugs Market Outlook, 2020 - 2033 6.1. Asia Pacific Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 6.1.1. Oral 6.1.2. Parenteral 6.1.3. Others 6.2. Asia Pacific Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.2.1. Hospitals 6.2.2. Specialty Clinics 6.2.3. Homecare Settings 6.2.4. Others 6.3. Asia Pacific Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 6.3.1. Antiepileptic Drugs 6.3.2. Antipsychotic Drugs 6.3.3. Antidepressants 6.3.4. Anticholinergic Drugs 6.3.5. Cholinesterase Inhibitors 6.3.6. NMDA Receptor Antagonists 6.3.7. Analgesics 6.3.8. Hypnotics & Sedatives 6.3.9. Anticoagulants 6.3.10. Others 6.4. Asia Pacific Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 6.4.1. Epilepsy 6.4.2. Alzheimer’s Disease 6.4.3. Parkinson’s Disease 6.4.4. Multiple Sclerosis 6.4.5. Cerebrovascular Disease 6.4.6. Migraine 6.4.7. Neuropathic Pain 6.4.8. Amyotrophic Lateral Sclerosis 6.4.9. Huntington’s Disease 6.4.10. Others 6.5. Asia Pacific Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 6.5.1. Hospital Pharmacies 6.5.2. Retail Pharmacies 6.5.3. Online Pharmacies 6.5.4. Others 6.6. Asia Pacific Neurological Disorder Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.6.1. China Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.2. China Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.3. China Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.4. China Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.5. China Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.6.6. Japan Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.7. Japan Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.8. Japan Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.9. Japan Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.10. Japan Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.6.11. South Korea Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.12. South Korea Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.13. South Korea Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.14. South Korea Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.15. South Korea Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.6.16. India Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.17. India Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.18. India Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.19. India Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.20. India Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.6.21. Southeast Asia Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.22. Southeast Asia Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.23. Southeast Asia Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.24. Southeast Asia Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.25. Southeast Asia Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.6.26. Rest of SAO Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 6.6.27. Rest of SAO Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 6.6.28. Rest of SAO Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 6.6.29. Rest of SAO Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 6.6.30. Rest of SAO Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 6.7. BPS Analysis/Market Attractiveness Analysis 7. Latin America Neurological Disorder Drugs Market Outlook, 2020 - 2033 7.1. Latin America Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 7.1.1. Oral 7.1.2. Parenteral 7.1.3. Others 7.2. Latin America Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.2.1. Hospitals 7.2.2. Specialty Clinics 7.2.3. Homecare Settings 7.2.4. Others 7.3. Latin America Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 7.3.1. Antiepileptic Drugs 7.3.2. Antipsychotic Drugs 7.3.3. Antidepressants 7.3.4. Anticholinergic Drugs 7.3.5. Cholinesterase Inhibitors 7.3.6. NMDA Receptor Antagonists 7.3.7. Analgesics 7.3.8. Hypnotics & Sedatives 7.3.9. Anticoagulants 7.3.10. Others 7.4. Latin America Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 7.4.1. Epilepsy 7.4.2. Alzheimer’s Disease 7.4.3. Parkinson’s Disease 7.4.4. Multiple Sclerosis 7.4.5. Cerebrovascular Disease 7.4.6. Migraine 7.4.7. Neuropathic Pain 7.4.8. Amyotrophic Lateral Sclerosis 7.4.9. Huntington’s Disease 7.4.10. Others 7.5. Latin America Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 7.5.1. Hospital Pharmacies 7.5.2. Retail Pharmacies 7.5.3. Online Pharmacies 7.5.4. Others 7.6. Latin America Neurological Disorder Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.6.1. Brazil Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 7.6.2. Brazil Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 7.6.3. Brazil Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 7.6.4. Brazil Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 7.6.5. Brazil Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 7.6.6. Mexico Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 7.6.7. Mexico Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 7.6.8. Mexico Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 7.6.9. Mexico Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 7.6.10. Mexico Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 7.6.11. Argentina Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 7.6.12. Argentina Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 7.6.13. Argentina Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 7.6.14. Argentina Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 7.6.15. Argentina Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 7.6.16. Rest of LATAM Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 7.6.17. Rest of LATAM Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 7.6.18. Rest of LATAM Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 7.6.19. Rest of LATAM Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 7.6.20. Rest of LATAM Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 7.7. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Neurological Disorder Drugs Market Outlook, 2020 - 2033 8.1. Middle East & Africa Neurological Disorder Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 8.1.1. Oral 8.1.2. Parenteral 8.1.3. Others 8.2. Middle East & Africa Neurological Disorder Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.2.1. Hospitals 8.2.2. Specialty Clinics 8.2.3. Homecare Settings 8.2.4. Others 8.3. Middle East & Africa Neurological Disorder Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 8.3.1. Antiepileptic Drugs 8.3.2. Antipsychotic Drugs 8.3.3. Antidepressants 8.3.4. Anticholinergic Drugs 8.3.5. Cholinesterase Inhibitors 8.3.6. NMDA Receptor Antagonists 8.3.7. Analgesics 8.3.8. Hypnotics & Sedatives 8.3.9. Anticoagulants 8.3.10. Others 8.4. Middle East & Africa Neurological Disorder Drugs Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033 8.4.1. Epilepsy 8.4.2. Alzheimer’s Disease 8.4.3. Parkinson’s Disease 8.4.4. Multiple Sclerosis 8.4.5. Cerebrovascular Disease 8.4.6. Migraine 8.4.7. Neuropathic Pain 8.4.8. Amyotrophic Lateral Sclerosis 8.4.9. Huntington’s Disease 8.4.10. Others 8.5. Middle East & Africa Neurological Disorder Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033 8.5.1. Hospital Pharmacies 8.5.2. Retail Pharmacies 8.5.3. Online Pharmacies 8.5.4. Others 8.6. Middle East & Africa Neurological Disorder Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.6.1. GCC Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 8.6.2. GCC Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 8.6.3. GCC Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 8.6.4. GCC Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 8.6.5. GCC Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 8.6.6. South Africa Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 8.6.7. South Africa Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 8.6.8. South Africa Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 8.6.9. South Africa Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 8.6.10. South Africa Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 8.6.11. Egypt Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 8.6.12. Egypt Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 8.6.13. Egypt Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 8.6.14. Egypt Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 8.6.15. Egypt Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 8.6.16. Nigeria Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 8.6.17. Nigeria Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 8.6.18. Nigeria Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 8.6.19. Nigeria Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 8.6.20. Nigeria Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 8.6.21. Rest of Middle East Neurological Disorder Drugs Market Outlook, by Route of Administration, 2020-2033 8.6.22. Rest of Middle East Neurological Disorder Drugs Market Outlook, by End User, 2020-2033 8.6.23. Rest of Middle East Neurological Disorder Drugs Market Outlook, by Drug Class, 2020-2033 8.6.24. Rest of Middle East Neurological Disorder Drugs Market Outlook, by Disease Type, 2020-2033 8.6.25. Rest of Middle East Neurological Disorder Drugs Market Outlook, by Distribution Channel, 2020-2033 8.7. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Pfizer Inc. 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Novartis AG 9.4.3. Johnson & Johnson 9.4.4. Eli Lilly and Company 9.4.5. AbbVie Inc. 9.4.6. Merck & Co., Inc. 9.4.7. Teva Pharmaceutical Industries Ltd. 9.4.8. UCB S.A. 9.4.9. Biogen Inc. 9.4.10. Sanofi S.A. 9.4.11. F. Hoffmann-La Roche Ltd. 9.4.12. Takeda Pharmaceutical Company Limited 9.4.13. Otsuka Pharmaceutical Co., Ltd. 9.4.14. Lundbeck A/S 9.4.15. Neurocrine Biosciences, Inc. 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（landscape）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
